Allogene Therapeutics
Matthew Porteus, MD, PhD is an Associate Professor of Pediatrics in the Department of Pediatrics, Divisions of Hematology/Oncology and Human Gene Therapy at Stanford University School of Medicine. He completed his combined MD/PhD at Stanford, with his PhD focused on understanding the molecular basis of mammalian forebrain development. After completing his dual degree program, Matthew completed an internship and residency in pediatrics at Boston Children’s Hospital and a pediatric hematology/oncology fellowship in the combined Boston Children’s Hospital/Dana Farber Cancer Institute program. For his fellowship and postdoctoral research, he worked with Nobel Laureate Dr. David Baltimore at the Massachusetts Institute of Technology and Caltech where he began his studies in developing homologous recombination as a strategy to correct disease-causing mutations in stem cells as definitive and curative therapy for children with genetic diseases of the blood, particularly sickle cell disease. Following his training with Dr. Baltimore, Matthew took an independent faculty position at UT Southwestern in the Departments of Pediatrics and Biochemistry before returning to Stanford as an Associate Professor.
This person is not in the org chart
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.